Zimmer Biomet Holdings Inc (ZBH)
Fair ValueFundamental
63
Price
$98.56
Market Cap
$18.09B
Part 1 · What the company is worth
Overview
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$8.51B
Trailing 12 months (through 6/30/2026)
Net Income
$807M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$1.47B
Total Equity
$12.70B
Total Liabilities
$10.39B
Current Ratio
1.69
Interest Coverage
4.17
Debt/EBITDA
3.41
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$110.40
Current Price
$98.56
Margin of Safety
+10.7%
Fair Value Range
$71.76 - $149.04
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
23.92
ROE
5.6%
P/B Ratio
1.49
P/FCF
12.34
Gross Margin
69.9%
ROIC
4.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
4.8%
WACC
6.6%
ROIC − WACC
-1.7 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (16)
- EPS shows upward trend
- Gross margin 69.9%
- P/FCF 12.34
- P/B ratio 1.49
- Debt/equity ratio
- Operating margin 14.2%
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- Earnings surprise, average 3.4%
- Earnings quality (operating cash flow / net income) 2.16
- Share dilution -2.6%
- Piotroski F-Score 5/9
Failed (9)
- EPS CAGR 0.47%
- Price CAGR -0.87%
- ROIC 4.8%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Fairly Valued)
- ROE 6.3%
- Revenue growth 5Y 3.2%
- Net margin trend 9.5% vs 10.5%
Unavailable (2)
- Dividend payout –
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Ivan Tornos | President, CEO & Chairman of the Board | 50 |
| Mr. Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 55 |
| Mr. JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 43 |
| Mr. Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 50 |
| Mr. Shaun Braun | Senior VP & Chief Information and Technology Officer | - |
| Dr. Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | - |
| Mr. David M. DeMartino | Senior Vice President of Investor Relations | - |
| Mr. Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 53 |
| Ms. Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | - |
| Ms. Kristen Cardillo | Senior VP & Chief Communications Officer | - |
Audit Risk
6
Board Risk
8
Compensation Risk
8
Shareholder Rights Risk
4
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-20
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-08
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much ZBH moves, measured on its daily prices.
More volatile than 39% of the tracked stocks (90-day volatility).
- Volatility 30d
- 30.7%
- Volatility 90d
- 32.0%
- Beta vs S&P 500 (1y)
- 0.12Correlation 0.05
- Max drawdown (12m)
- -22.9%
- ATR (14d, % of price)
- 2.51%
Earnings reactions
How ZBH moved around its past quarterly results.
Next earnings release
Nov 4, 2026 · In 11 days · Before the open
EPS estimate: 1.88Revenue estimate: $2.0B
What usually happens
- Over the last 12 releases the stock moved a median of 4.3% the next day, up or down.
- Next-day moves: up 4, down 8 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | During the session | 2.03 | 2.07 | +2.0% | +5.4% | +2.5% | +1.5% |
| Apr 28, 2026 | During the session | 1.88 | 2.09 | +11.0% | -5.4% | -10.6% | -10.7% |
| Feb 10, 2026 | During the session | 2.42 | 2.42 | 0.0% | +4.9% | +1.9% | +8.3% |
| Nov 5, 2025 | During the session | 1.89 | 1.90 | +0.7% | -12.1% | -15.1% | -14.2% |
| Aug 7, 2025 | During the session | n/a | n/a | n/a | +5.2% | +8.0% | +13.2% |
| May 5, 2025 | During the session | n/a | n/a | n/a | -2.7% | -11.6% | -7.0% |
| Feb 6, 2025 | During the session | n/a | n/a | n/a | -3.9% | -5.1% | -8.6% |
| Oct 30, 2024 | During the session | n/a | n/a | n/a | +3.5% | +5.7% | +4.9% |
| Aug 7, 2024 | During the session | n/a | n/a | n/a | -2.6% | -3.4% | -0.2% |
| May 2, 2024 | During the session | n/a | n/a | n/a | +2.0% | -0.9% | +1.1% |
| Feb 8, 2024 | During the session | n/a | n/a | n/a | -5.4% | -3.5% | -4.5% |
| Nov 7, 2023 | During the session | n/a | n/a | n/a | -2.9% | -3.1% | -3.2% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on ZBH and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for ZBH.